{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=45", "query": { "intervention": "Formulation #1", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 1760, "total_pages": 176, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=44&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T15:01:03.230Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02783300", "title": "An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK3326595", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 297, "start_date": "2016-08-30", "completion_date": "2023-08-30", "has_results": true, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-11-06T15:01:03.230Z", "location_count": 6, "location_summary": "Denver, Colorado • Miami, Florida • New York, New York + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02783300" }, { "nct_id": "NCT06244316", "title": "A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dry Eye Disease" ], "interventions": [ { "name": "rhNGF 5 μg/mL", "type": "DRUG" }, { "name": "rhNGF 10 μg/mL", "type": "DRUG" }, { "name": "Vehicle (Placebo solution)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dompé Farmaceutici S.p.A", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2024-01-22", "completion_date": "2024-12-04", "has_results": true, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-11-06T15:01:03.230Z", "location_count": 10, "location_summary": "Chandler, Arizona • Torrance, California • Colorado Springs, Colorado + 7 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Torrance", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06244316" }, { "nct_id": "NCT02258321", "title": "Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetic Assessments in Healthy Volunteers" ], "interventions": [ { "name": "PPI-668 tablet", "type": "DRUG" }, { "name": "PPI-668 capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Presidio Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2014-10", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-01-22", "last_synced_at": "2026-11-06T15:01:03.230Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02258321" }, { "nct_id": "NCT06641596", "title": "Impact of Chromium, Phyllanthus Emblica, and Shilajit on Cardiovascular Health, Fitness, and Weight Loss During Exercise and Diet Programs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Overweight", "Metabolic Syndrome X" ], "interventions": [ { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" }, { "name": "Cr-400", "type": "DIETARY_SUPPLEMENT" }, { "name": "Cr-800", "type": "DIETARY_SUPPLEMENT" }, { "name": "PE-500", "type": "DIETARY_SUPPLEMENT" }, { "name": "PE-1000", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Kerry Group P.L.C", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "30 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "30 Years to 65 Years" }, "enrollment_count": 112, "start_date": "2019-02-01", "completion_date": "2024-05-29", "has_results": false, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-11-06T15:01:03.230Z", "location_count": 1, "location_summary": "College Station, Texas", "locations": [ { "city": "College Station", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06641596" }, { "nct_id": "NCT04782687", "title": "Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Myeloma Multiple", "Kahler Disease", "Myeloma, Plasma Cell", "Myeloma-Multiple", "Myelomatosis", "Plasma Cell Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone Oral", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2021-09-10", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-11-06T15:01:03.230Z", "location_count": 10, "location_summary": "Tucson, Arizona • Denver, Colorado • Columbia, Maryland + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Albany", "state": "New York" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04782687" }, { "nct_id": "NCT01877421", "title": "Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Plaque", "Gingivitis" ], "interventions": [ { "name": "2 mg KSL-W", "type": "DRUG" }, { "name": "4 mg KSL-W", "type": "DRUG" }, { "name": "6 mg KSL-W", "type": "DRUG" }, { "name": "10 mg KSL-W", "type": "DRUG" }, { "name": "20 mg KSL-W", "type": "DRUG" }, { "name": "30 mg KSL-W", "type": "DRUG" }, { "name": "50 mg KSL-W", "type": "DRUG" }, { "name": "75 mg KSL-W", "type": "DRUG" }, { "name": "100 mg KSL-W", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "U.S. Army Medical Research and Development Command", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 135, "start_date": "2014-02-25", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2020-02-13", "last_synced_at": "2026-11-06T15:01:03.230Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01877421" }, { "nct_id": "NCT01759056", "title": "Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "AVX 470", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avaxia Biologics, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 33, "start_date": "2013-02", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-11-06T15:01:03.230Z", "location_count": 9, "location_summary": "Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Winter Park", "state": "Florida" }, { "city": "Chevy Chase", "state": "Maryland" }, { "city": "Chesterfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01759056" }, { "nct_id": "NCT07626281", "title": "Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Inclisiran Formulation" ], "interventions": [ { "name": "Inclisiran formulation containing PS80", "type": "DRUG" }, { "name": "Currently marketed inclisiran formulation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 152, "start_date": "2026-06-09", "completion_date": "2026-12-21", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-06T15:01:03.230Z", "location_count": 6, "location_summary": "Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah", "locations": [ { "city": "Lenexa", "state": "Kansas" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07626281" }, { "nct_id": "NCT02926430", "title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ad26.RSV.preF 5*10^10 vp", "type": "BIOLOGICAL" }, { "name": "Ad26.RSV.preF 1*10^11 vp", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Janssen Vaccines & Prevention B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 73, "start_date": "2016-11-08", "completion_date": "2019-01-29", "has_results": false, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-11-06T15:01:03.230Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02926430" }, { "nct_id": "NCT07893093", "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Weight Management" ], "interventions": [ { "name": "ASC36 Injection A, for subcutaneous use", "type": "DRUG" }, { "name": "ASC36 Placebo Injection A, for subcutaneous use", "type": "DRUG" }, { "name": "ASC36 Injection B, for subcutaneous use", "type": "DRUG" }, { "name": "ASC36 Placebo Injection B, for subcutaneous use", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascletis Pharma (China) Co., Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 144, "start_date": "2026-09-28", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-11-06T15:01:03.230Z", "location_count": 2, "location_summary": "San Antonio, Texas • Salt Lake City, Utah", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07893093" } ] }